Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 4/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805525 | 1.00 | MTNR1B (0.51) | MTNR1BMTNR1ACHRNA7NQO2KDM1A | |
| SCHEMBL1478135 | 1.00 | MTNR1B (0.51) | MTNR1BMTNR1ACHRNA7NQO2KDM1A | |
| SCHEMBL326892 | 0.90 | MTNR1A (0.54) | MTNR1BMTNR1ANQO2HTR2AHTR2C | |
| SCHEMBL11142664 | 0.89 | HTR2A (0.47) | MTNR1BMTNR1ANQO2HTR2AHTR2C | |
| SCHEMBL345441 | 0.87 | CHRNA7 (0.50) | CHRNA7HTR2CGID4SIGMAR1 | |
| SCHEMBL3069878 | 0.82 | CHRNA7 (0.49) | CHRNA7HTR2C | |
| SCHEMBL29588202 | 0.81 | HTR2C (0.62) | MTNR1BMTNR1ACHRNA7KDM1AMAOA | |
| SCHEMBL2970487 | 0.81 | HTR2C (0.62) | MTNR1BMTNR1ACHRNA7KDM1AMAOA | |
| SCHEMBL13306289 | 0.81 | HTR2C (0.62) | MTNR1BMTNR1ACHRNA7KDM1AMAOA | |
| SCHEMBL6797994 | 0.81 | HTR2C (0.62) | MTNR1BMTNR1ACHRNA7KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750243-B1 | COMPETITIVE INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASES, ESPECIALLY THROMBIN; chemical synthesis; anticoagulants; treatment of thrombosis | AstraZeneća AB (SE) | 2004-06-15 | — | — | US | claimed |
| EP-2772476-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | HAMARI CHEMICALS LTD (JP) | 2017-01-11 | — | — | EP | disclosed |
| US-9174899-B2 | Method for producing optically active alcohols | HAMARI CHEMICALS, LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20140296584-A1 | Method for Producing Optically Active Alcohols | HAMARI CHEMICALS, LTD. (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2772476-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Hamari Chemicals, Ltd. (JP) | 2014-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296584-A1 | Method for Producing Optically Active Alcohols | ADH5, ADH1C, ADH1A | MTNR1B 3389/4885MTNR1A 3907/4885CHRNA7 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.